Phase 1b trial of pembrolizumab monotherapy for relapsed/refractory multiple myeloma: KEYNOTE‐013
Open accessAbstract
Comparison of lowintensity warfarin therapy with conventionalintensity warfarin therapy for long-term prevention of recurrent venous thromboembolism.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Pembrolizumab monotherapy showed limited efficacy in both relapsed/refractory multiple myeloma and autologous stem cell transplantation patients.
“Additionally, pembrolizumab monotherapy showed limited efficacy in both RRMM and ASCT patients [178].”
From Multiple myeloma: signaling pathways and targeted therapy (2024) · cites this paper as [178]
Cites
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Dimopoulos, M. A., Oriol, A., Nahi, H., San-Miguel, J., Bahlis, N. J., Usmani, S. Z., Rabin, N., Orlowski, R. Z., Komarnicki, M., Suzuki, K., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607751 · Cited by 1,445 · see citing works
Pembrolizumab, pomalidomide, and low-dose dexamethasone for relapsed/refractory multiple myeloma
Badros, A., Hyjek, E., Ma, N., Lesokhin, A., Dogan, A., Rapoport, A. P., Kocoglu, M., Lederer, E., Philip, S., Milliron, T., et al. (2017) · Blood · doi:10.1182/blood-2017-03-775122 · Cited by 197 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Multiple myeloma: signaling pathways and targeted therapy
Lu, Q., Yang, D., Li, H., Niu, T., & Tong, A. (2024) · Molecular biomedicine · doi:10.1186/s43556-024-00188-w · Cited by 90 · see citing works
- Authors
- Ribrag, V., Avigan, D. E., Green, D. J., Wise‐Draper, T., Posada, J. G., Vij, R., Zhu, Y., Farooqui, M. Z. H., Marinello, P., & Siegel, D. S.
- Affiliations
- Institut Gustave Roussy (FR)
- Beth Israel Deaconess Medical Center (US)
- University of Washington (US)
- University of Cincinnati Cancer Institute Cincinnati OH
- Central Texas Veterans Health Care System (US)
- Washington University in St. Louis (US)
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Hackensack University Medical Center (US)
- Corresponding author
- Ribrag, Vincent
- ORCID
- Venue
- British Journal of Haematology
- Publisher
- Wiley
- Published
- 2019-04
- Volume
- 186
- Issue
- 3
- Pages
- e41-e44
- ISSN
- 0007-1048 (ISSN-L)
- 1365-2141
- OpenAlex
- W2928218072
- Cited by
- 82
- References
- 2
- Citations by year
- 2026: 2 · 2025: 7 · 2024: 20 · 2023: 5 · 2022: 12 · 2021: 18 · 2020: 12 · 2019: 5 · 2018: 1
- FWCI
- 8.30
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- British Journal of Haematology (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- Funders
- Merck Sharp and Dohme
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Pathology and Forensic Medicine › Multiple Sclerosis Research Studies
- Keywords
- pembrolizumab, multiple myeloma, relapsed/refractory multiple myeloma, immune checkpoint inhibitors, monotherapy, anti-PD-1 therapy
- MeSH terms
- Antineoplastic Agents, Immunological, Female, Humans, Male, Multiple Myeloma, Recurrence, Cohort Studies, Survival Analysis, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
